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Abstract
Background: p21WAF1, implicated in the cell cycle control of both normal and malignant cells, can be induced by p53-dependent
and independent mechanisms. In some cells, MEKs/ERKs regulate p21WAF1 transcriptionally, while in others they also affect the
post-transcriptional processes. In myogenic differentiation, p21WAF1 expression is also controlled by the myogenic transcription
factor MyoD. We have previously demonstrated that the embryonal rhabdomyosarcoma cell line undergoes growth arrest and
myogenic differentiation following treatments with TPA and the MEK inhibitor U0126, which respectively activate and inhibit
the ERK pathway.
In this paper we attempt to clarify the mechanism of ERK-mediated and ERK-independent growth arrest and myogenic
differentiation of embryonal and alveolar rhabdomyosarcoma cell lines, particularly as regards the expression of the cell cycle
inhibitor p21WAF1.
Results: p21WAF1 expression and growth arrest are induced in both embryonal (RD) and alveolar (RH30) rhabdomyosarcoma
cell lines following TPA or MEK/ERK inhibitor (U0126) treatments, whereas myogenic differentiation is induced in RD cells
alone. Furthermore, the TPA-mediated post-transcriptional mechanism of p21WAF1-enhanced expression in RD cells is due to
activation of the MEK/ERK pathway, as shown by transfections with constitutively active MEK1 or MEK2, which induces p21WAF1
expression, and with ERK1 and ERK2 siRNA, which prevents p21WAF1 expression. By contrast, U0126-mediated p21WAF1
expression is controlled transcriptionally by the p38 pathway. Similarly, myogenin and MyoD expression is induced both by
U0126 and TPA and is prevented by p38 inhibition. Although MyoD and myogenin depletion by siRNA prevents U0126-mediated
p21WAF1 expression, the over-expression of these two transcription factors is insufficient to induce p21WAF1. These data suggest
that the transcriptional mechanism of p21WAF1 expression in RD cells is rescued when MEK/ERK inhibition relieves the functions
of myogenic transcription factors. Notably, the forced expression of p21WAF1 in RD cells causes growth arrest and the reversion
of anchorage-independent growth.
Conclusion:  Our data provide evidence of the key role played by the MEK/ERK pathway in the growth arrest of
Rhabdomyosarcoma cells. The results of this study suggest that the targeting of MEK/ERKs to rescue p21WAF1 expression and
myogenic transcription factor functions leads to the reversal of the Rhabdomyosarcoma phenotype.
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Background
Permanent withdrawal from the cell cycle is a crucial event
during terminal differentiation. Dysfunction of either cell
cycle control or differentiation machinery is responsible
for deregulated growth and transformed phenotype [1].
Control of G1/S transition is regulated by a set of specific
CDK and cyclin complexes, sequentially expressed, acti-
vated and degraded to ensure both entry and progress in
the cell cycle [2]. In large part, the cyclin/CDK complexes
are needed to phosphorylate pRb, which in turn releases
E2F and leads to the transcription of growth regulating
genes such as cyclin A [3].
p21WAF1, a cyclin-dependent kinase inhibitor (CKI),
which inhibits all cyclin/CDK complexes, particularly
those in the G1 phase, has been found to be associated
with the growth arrest of both normal and malignant cells
[4]. Enhanced p21WAF1 mRNA expression occurs through
both p53-dependent and -independent mechanisms
[5,6], and as a result of mRNA and protein stabilization
induced in a number of different cell lines and signal
transduction mechanisms [6-9].
In myogenic cells, muscle-specific transcription factors,
such as MyoD, induce transcription of p21WAF1 during dif-
ferentiation [10,11], while in mice lacking MyoD and
myogenin, muscle precursors correctly express p21WAF1,
suggesting that this important cell cycle molecule is con-
trolled by a redundant transcription factor regulatory
mechanism [12]. Although hypo-phosphorylated pRb
expression is up regulated during myoblast-to-myotube
transition and after myogenic differentiation, the pRb
kinases CDK4 and CDK6 are constitutively expressed,
while CDK2 undergoes down-regulation during terminal
myogenic differentiation [10,11].
The MEK/ERK pathways control the growth and survival
of a broad spectrum of human tumors [13], and have also
been involved in differentiation [14-16]. Indeed, a role of
the MEK/ERK pathway in growth inhibition has been
reported to be dependent upon whether activation is
acute or chronic [17]. Although ERKs are constitutively
activated in tumor growth and are involved in the induc-
tion of proliferation, a high p38 level is believed to be a
negative regulator [18,19]. Furthermore, the ERK and p38
pathways have recently been reported to cooperate to
cause sustained G1 cell cycle arrest requiring p21WAF1
expression [20].
Rhabdomyosarcoma (RMS), the most common soft-tis-
sue sarcoma arising from undifferentiated mesenchymal
cells bearing developing skeletal muscle features, consists
of several subtypes, with ERMS, the embryonal subtype,
and ARMS, the alveolar subtype, being among the most
frequent tumors in children [21]. RMS presents a number
of genetic alterations which define the embryonal [22,23]
and the alveolar subtype [24]. These different subtypes
also share molecular changes, including disruption of the
p53 pathway through mutation or MDM2 amplification,
and deregulation of imprinted genes at the chromosome
region 11p15.5 [22,25].
The established RD cell line, originating from the ERMS
tumor, is one of the most representative models of patho-
logical myogenesis. RD cells fail to control cell cycle
mechanisms [26] and differentiation progress in spite of
the expression of the myogenic-specific transcription fac-
tors MyoD and myogenin, which are transcriptionally
inactive despite apparently being able to bind DNA
[23,27]. MyoD and myogenin, when ectopically
expressed in RD cells, do not induce muscle differentia-
tion, even in the presence of cyclin-dependent kinase
inhibitors (CKIs) or myogenic co-factors [28], while
ectopic expression of MRF4, which is undetectable in RD,
induces exit from the cell cycle and myogenic differentia-
tion, both of which are enhanced in the presence of CKIs
[29].
In a recent paper, we demonstrated that PKC-α-mediated
MAPK (ERKs, JNKs and p38) activation is responsible for
orchestrating growth arrest and myogenic differentiation
induced by the phorbol ester TPA [30]. It is noteworthy
that the use of the specific MEK inhibitor allowed us to
selectively inhibit MAPK activation, thereby showing that
ERKs represent the key pathway to growth arrest and myo-
genic differentiation when either activated or inhibited.
In this paper we attempt to clarify the mechanism of ERK-
mediated and ERK-independent growth arrest and myo-
genic differentiation in RD cells, particularly with regard
to the expression of proteins involved in cell cycle control,
such as p21WAF1. We demonstrate that p21WAF1 expression
is post-transcriptionally regulated by TPA-mediated MEK/
ERK activation, but transcriptionally induced by MEK/
ERK inhibition and p38 activation.
Furthermore, we present evidence of p21WAF1 expression-
dependence on myogenin and MyoD activity. In spite of
the features shared by growth arrest and p21WAF1
enhanced expression, RH30 cells do not undergo myo-
genic differentiation either under TPA or MEK inhibitor
treatments. In this paper we also show that p21WAF1 is
involved in regulating anchorage-independent growth of
RD cells.Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
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Expression of cell cycle markers during growth arrest induced by TPA Figure 1
Expression of cell cycle markers during growth arrest induced by TPA. RD cells were treated with 10-7 M TPA for 
the times indicated. (A) whole cell lysates from untreated (-) or TPA-treated cells (+) were separated on 12% SDS-PAGE and 
analysed by immunoblotting with specific antibodies for the proteins indicated. α-tubulin expression shows equal loading. pRb 
was analysed on a filter from 7% SDS-PAGE. Densitometric analysis of bands provided quantification expressed as the ratio of 
cell cycle protein amount versus the α-tubulin amount. (B) Northern blots from total RNA of untreated (-) and TPA-treated 
cells (+). The loading was tested by reprobing the same filters with GAPDH. Densitometric analysis of bands provided quantifi-
cation as the ratio of the amount of mRNA cell cycle protein versus mRNA GAPDH amount. The data shown are representa-
tive of three independent experiments.
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Results
Sustained post-transcriptional and transient 
transcriptional p21WAF1 expression respectively after ERK 
pathway activation and down-regulation
In order to identify the molecular mechanism of G1 arrest
following ERK activation and MEK/ERK inhibition in RD
cells (see additional file 1), we first determined the pattern
of G1/S cyclins, CDKs and CDK inhibitor proteins after
TPA and U0126 treatments.
Total lysates from RD cells, left untreated or treated with
TPA for different time intervals, were analysed by immu-
noblotting with a panel of antibodies aimed at the cell
cycle proteins. We analysed the expression level of
p21WAF1, known to particularly inhibit the G1 cell cycle
complexes. p21WAF1 was rapidly (after 30 min), markedly
(5–18 fold from 30 min to 12 hrs) and permanently (4
fold up to 4 days) increased by TPA treatment (Fig. 1A).
Remarkably, the p21WAF1  level in the control cells
Expression of cell cycle markers modulated by U0126 Figure 2
Expression of cell cycle markers modulated by U0126.RD cells were treated with 10 µM U0126 for the times indi-
cated. (A) whole cell lysates from untreated (-) or U0126-treated cells (+) were separated on 12% SDS-PAGE and analysed by 
immunoblotting with specific antibodies for the proteins indicated. α-tubulin expression shows equal loading. pRb was analysed 
on a filter from 7% SDS-PAGE. Densitometric analysis of bands provided quantification expressed as the ratio of the amount of 
cell cycle protein versus α-tubulin amount. (B) Graph shows the quantification of the results presented in A expressed as a fold 
increase of the indicated cell cycle protein in the U0126 sample over the untreated sample at the time points examined. (C) 
Northern blot from total RNA of untreated (-) and U0126-treated cells (+). Loading was tested by reprobing the same filter 
with GAPDH. Densitometric analysis of bands provided quantification as the ratio of the amount of mRNA cell cycle protein 
versus mRNA GAPDH amount. The data shown are representative of two independent experiments.
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remained steady up to 2 days and increased at 4 days, even
though TPA-induced p21WAF1 expression exceeded by far
the level of its respective control. Moreover, cyclin D1 was
up-regulated early and permanently during TPA treatment
(Fig. 1A, 30 min-4 days), while cyclin A and B1 were
down-regulated later (2–4 days). p27, CDK2, CDK4, cyc-
lin D3 and cyclin E were virtually unaltered throughout
the treatment (see additional file 2). To corroborate the
G1 arrest pattern, we investigated the pRb phosphoryla-
tion level, known to be down-regulated during G1 arrest
[31]. pRb was heavily phosphorylated in both untreated
and TPA-treated cells during the first 12 hours of treat-
ment; by contrast, from after 1 day up to 4 days of treat-
ment the hypo-phosphorylated isoform was easily
detectable (Fig. 1A), suggesting that inhibition of G1/S
progression occurs. Northern blot experiments revealed a
sustained increase in p21WAF1 and cyclin D1 mRNAs (Fig.
1B) after both early and prolonged TPA treatment. We
then analysed p21WAF and cyclin D1 expression by immu-
noblotting total lysates from RD cells, left untreated or
treated with the MEK inhibitor U0126. Similarly to TPA,
U0126 induced an early increase in p21WAF1 (30 min-2
days), though at varying levels (1.2–3.7 fold from 30 min
up to 12 hrs, and 4.4 fold at 2 days) (Fig. 2A). While
p21WAF1 expression was sustained following TPA treat-
ment (Fig. 1, 30 min-4 days), in U0126-treated cells it
decreased from 2 to 4 days after treatment, as shown in
Figure 2A. Notably, p27 expression progressively
increased in U0126-treated cells from 1.7 (30 min) to 4.4
fold if compared with control untreated cells. Unlike
p21WAF1, cyclin D1 expression dropped to below the level
of control untreated cells from as early as 6 hours and up
to 4 days after treatment. In addition, the hypo-phospho-
rylated form of pRb was detected as early as 12 hours after
the start of treatment and was sustained for up to 4 days.
Interestingly, the quantification of the levels of p21WAF1,
p27 and cyclin D1 expression in early (1 hr), middle (1
day) and late (4 day) U0126 treatments shows how key
cell cycle protein levels are inversely correlated, with
p21WAF1 dropping when p27 peaks and cyclin D1 also
drops (Fig. 2B). Northern blot analysis shows that the
p21WAF1 transcript increases during the first day of U0126
treatment, before dropping to the basal level after pro-
longed treatment (from 3 to 4 days), whereas the cyclin
D1 transcript is down-regulated by the inhibitor, thereby
confirming the protein pattern in Western blot (Fig. 2C).
We hypothesized that the differences in the expression
and accumulation of p21WAF1 in cells bearing the acti-
vated (TPA-treated) or inhibited (U0126-treated) MEK/
ERK pathway might be due to transcriptional and/or post-
transcriptional mechanisms [7,32]. For this purpose, we
first investigated ectopic p21WAF1 promoter transactiva-
tion upon TPA treatment in transiently transfected cells.
RD cells were transfected with a vector expressing luci-
ferase under the control of the p21WAF1 promoter (DM-
Luc) together with the β-galactosidase expression vector,
and were left untreated or were treated with TPA for 24
hours. Luciferase and β-galactosidase activities were eval-
uated in total lysates. TPA did not increase luciferase activ-
ity (Fig. 3A).
mRNA stabilization by TPA and transcriptional activation by  U0126 of p21WAF1 expression Figure 3
mRNA stabilization by TPA and transcriptional acti-
vation by U0126 of p21WAF1 expression.(A). RD cells 
were transfected with plasmid expressing β-galactosidase (β-
gal) gene and a plasmid carrying p21 promoter (DM-Luc). 
Luciferase activity was normalized for the expression levels 
of transfected β-gal protein. Data show mean values ± s.e.m. 
of triplicates of a representative experiment. (B) Northern 
blots from RD cells left untreated (C) or treated with TPA 
(upper panel) or U0126 (U) (lower panel) for 5 hours, pre-
treated with 0.05 µg/ml of actinomycin D for 1 hour and 
then left untreated (ActD) or treated with TPA (ActD+TPA) 
or U0126 (ActD+U) for 5 hours. The levels of GAPDH 
mRNA are shown. Similar results were obtained in three 
independent experiments for A and two for B.
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In order to ascertain whether the increase in p21WAF1
mRNA was a result of mRNA stabilization, actinomycin
D-pre-treated (1 hr) cells were left untreated or were
treated with TPA for 5 hours, and mRNAs were analysed
in Northern blot, as shown in Figure 3B (upper panel). In
TPA-treated cells, actinomycin-D did not, unlike control
untreated cells (Act-D), suppress the p21WAF1 mRNA tran-
script (Act-D TPA). This result indicates that the TPA-
mediated p21WAF1 increase is a result of a post-transcrip-
tional mechanism, which suggests mRNA stabilization [6-
9].
Unlike TPA, MEK/ERK inhibition induces p21WAF1 expres-
sion through a transcriptional mechanism, as demon-
strated by Northern blot of U0126-treated cells after
actinomycin D pre-treatment (Fig. 3B, lower panel). Pre-
treatment with actinomycin D completely prevented
U0126-mediated induction of the p21WAF1  transcript,
thereby indicating that MEK/ERK inhibition restores the
p21WAF1 transcription mechanism.
Furthermore, actinomycin D did not alter p21WAF1 expres-
sion at the protein level in either untreated cells or TPA-
treated cells, but it drastically prevented the U0126-medi-
ated increase in the p21WAF1 protein (see additional file 3).
A protein stabilization mechanism was tested in cells
treated with TPA for 1 hour followed by cycloheximide for
varying time intervals. In TPA-treated cells, cycloheximide
prevented the increase in the level of p21WAF1, thereby
demonstrating that TPA does not induce any protein sta-
bilization mechanism (see additional file 3 ). These data,
taken as a whole, demonstrate that p21WAF1 accumulation
is a result of post-transcriptional or transcriptional mech-
anisms when the MEK/ERK pathway is, respectively, active
or inactive, which suggests that p21WAF1-induced expres-
sion is an early event in the attainment of growth arrest
that is targeted by opposite pathways.
Sustained post-transcriptional p21WAF1 expression is 
dependent on ERK activation
In order to establish whether sustained activation of the
MEK/ERK pathway plays a role in post-transcriptional-
mediated p21WAF1  accumulation, RD cells, pre-treated
with U0126, were treated with TPA for different time
intervals. p21WAF1 protein accumulation was insensitive to
MEK inhibitor treatment for up to 2 days, after which it
dropped to the level of untreated control cells, paralleling
U0126 treatment alone (Figure 4A). These results suggest
that the post-transcriptional mechanism of p21WAF1
induction might be strictly dependent on activated MEK/
ERK pathway. Constitutively active MEK1 or MEK2 (Fig.
4B) and ERK1 and ERK2 siRNA (Fig. 4C) transient trans-
fection experiments demonstrated that activated MEKs/
ERKs are upstream pathways of p21WAF1 expression. The
forced expression of MEK1 or MEK2 induced both ERK
phosphorylation and p21WAF1-increased expression (Fig.
4B). RNA interference experiments were performed with
both ERK1 and ERK2 siRNA in order to prevent TPA-
induced ERK1/2 activation. After 4 days of TPA treatment,
we observed a lack of p21WAF1 expression combined with
the down-regulation of total and phospho-ERKs in ERK1
and ERK2 siRNA co-transfected cells, while ERK activation
and p21WAF1 expression were present in control trans-
fected cells (siRNA-C) (Fig. 4C). All these experiments
demonstrate that the post-transcriptional mechanism of
p21WAF1 expression is dependent on the ERK pathway in
RD cells.
Dependence of p21WAF1 transcriptional expression and 
myogenic differentiation on the p38 pathway
We have previously shown that the p38 pathway is acti-
vated concomitantly in both the activation and down-reg-
ulation of the ERK pathway, and that its inhibition
prevents myogenic differentiation and reverts the growth
arrest state after prolonged treatment [30]. Therefore, we
investigated whether ERKs and p38 cooperate, as has
recently been demonstrated in CC139 and Rat-1 cells
[20], or act separately to induce p21WAF1 and growth
arrest. For this purpose, RD cells were treated with TPA
and U0126 in the presence or absence of the p38 specific
inhibitor SB203580. SB203580 treatment did not alter
TPA-induced p21WAF1  expression, but it did reduce
U0126-induced p21WAF1 expression, particularly after pro-
longed treatments (from 2 to 5 days, Fig. 5A); alone it
only slightly enhanced the p21WAF1 basal level (1.4 fold).
Furthermore, p38 inhibition affected neither the TPA-
induced expression of cyclin D1 nor the decrease medi-
ated by MEK/ERK inhibition (see additional file 4). The
pRb phosphorylation status is, moreover, modulated by
SB203580 after 2 days in U0126 treated cells (Fig 5B).
Conversely, pRb phosphorylation in TPA-treated cells is
insensitive to SB203580. SB203580 alone does not affect
pRb phosphorylation and the slight increase in p21WAF1
expression (1.4 fold) at prolonged treatments is not suffi-
cient to induce hypo-phosphorylation of pRb (Fig. 5B).
Analysis of p21WAF1  mRNA accumulation following
U0126 treatment in the presence and absence of
SB203580 (Fig. 5C) shows that the p21WAF1 transcript was
reduced by p38 inhibitor, thereby paralleling the Western
blot results and suggesting that the p38 pathway is
involved in transcriptional p21WAF1 induction by U0126.
Since growth arrest and myogenic differentiation in ERK
pathway-depleted cells is induced rapidly [30], it is possi-
ble that p21WAF1 is an early downstream target of activated
myogenic transcription factors, as occurs in normal myo-
genic myoblasts [10]. In order to verify this hypothesis, we
first analysed the levels of MyoD and myogenin following
U0126 treatment. The myogenin transcript was strongly
enhanced in U0126-treated cells for the first day of treat-Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
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ment but decreased thereafter, thus resembling the pat-
tern of the p21WAF1 transcript (Fig. 5C). The increase in the
MyoD transcript was also detectable from 1 day but
decreased thereafter. It is noteworthy that SB203580
inhibits both myogenin and MyoD transcript expression
in control untreated and in U0126-treated cells, thereby
resembling the p21WAF1 expression pattern. Immunoblot-
ting analysis showed that the myogenin protein level was
strongly enhanced by U0126, and to a higher degree than
it was by TPA (Fig. 6). The MyoD protein level in U0126-
treated cells increases together with a slow migrating
form, which may be its hypo-phosphorylated isoform
(Fig. 6, 2–4 days). The early induction of a differentiative
pathway is corroborated by early myosin expression in 2-
day U0126-treated cells, though not in the 2-day TPA-
treated cells (Fig. 6). It is noteworthy that concomitant
U0126 and TPA treatments of both myogenin and myosin
expression are cumulative (Fig. 6). Furthermore, p38 inhi-
bition by SB203580 reduces the slow migrating form of
MyoD, as well as early and late myogenin and myosin
expression in both TPA- and U0126-treated cells (Fig. 6).
Lastly, to validate the efficiency of SB203580 at longer
incubation times, we compared its effects on myogenin
expression with those of its inactive analogue SB202474,
which has been shown not to block the p38 pathway
[33,34].
Treatment with SB202474 does not affect either basal or
TPA-induced myogenin expression after a short or longer
pre-incubation period (see additional file 5). These results
MEK/ERK pathway sustains p21WAF1 expression Figure 4
MEK/ERK pathway sustains p21 WAF1 expression. (A) RD cells were left untreated (-) or treated with TPA in the 
absence or in the presence of U0126 for the times indicated. (B) RD cells were transfected with the constitutively active form 
of HA-tagged-MEK1 (ca MEK1), -MEK2 (ca MEK2) or with the empty vector (CMV). (C) RD cells were transfected with con-
trol siRNA (siRNA-C) or ERK1 and ERK2 siRNAs (siRNAERK1-2) and then left untreated (-) or treated with TPA (+) for 4 
days. Immunoblots of total lysates were performed using specific antibodies capable of recognising p21WAF1, total and phospho-
rylated ERK1/2, hemagglutinin (HA) and α-tubulin. The data shown are representative of three independent experiments for A 
and two for B and C.
12h 2d 5d
p21
α α α α-tubulin
- +       - +        - +       - +          - +      - +     TPA 
- - +      +        - - +      +          - - +      +     U0126
A
CMV 
ca MEK1
ca MEK2
p21
HA
ERK-PO4
B
p-ERK1/2
p21
TPA -+ -+
siRNA-C siRNAERK1-2
C
α α α α-tubulin
ERK1/2Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
Page 8 of 18
(page number not for citation purposes)
demonstrate that p21WAF1 expression is dependent on the
p38 pathway in the absence of active MEKs/ERKs, but is
fully independent in the presence of activated ERKs,
thereby suggesting that ERK and p38 do not cooperate in
p21WAF1 expression.
p21WAF1 expression is dependent on MyoD and myogenin
We then decided to investigate whether the transcrip-
tional mechanism of U0126-mediated p21WAF1 expres-
sion is a result of restored myogenic transcription factor
function. For this purpose, we performed two different
experiments designed to clarify, on the one hand, whether
myogenin and MyoD depletion impairs U0126-mediated
p21WAF1  expression and, on the other, whether their
increased levels rescue p21WAF1 expression. We first per-
formed siRNA experiments using control, myogenin and
MyoD siRNAs in transient transfection, followed by 2
days of U0126 treatment. Figure 7A shows that MyoD and
myogenin siRNA efficiently abrogated basal and U0126-
induced protein expression, when used either alone or in
Effects of p38 inhibition on p21WAF1, myogenin and MyoD expression Figure 5
Effects of p38 inhibition on p21WAF1, myogenin and MyoD expression. (A and B) RD cells were left untreated, treated 
with TPA or U0126 or pre-treated with 5 µM SB 203580 for 1 hour and then left untreated or treated with TPA or U0126 for 
the times indicated. Immunoblots of total lysates were performed using specific antibodies recognising p21WAF1 and α-tubulin 
(A) and pRb (B). Densitometric analysis of bands provided quantification expressed as the ratio of amount of p21WAF1 versus α-
tubulin amount. (C) Northern blot analysis of p21WAF1, myogenin and MyoD expression in RD cells left untreated or treated 
with U0126 in the absence or in the presence of SB 203580 for the times indicated. The GAPDH mRNA levels are shown. The 
data shown are representative of three independent experiments for A and B and two for C.
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combination, and also abrogated each other's protein
expression (Fig. 7A, see MyoD in myogenin siRNA and
vice versa). U0126-mediated p21WAF1 expression was pre-
vented in myogenin and MyoD siRNAs, as well as in com-
bined myogenin and MyoD siRNAs, whereas it was
unaffected in control siRNA-transfected cells (Fig. 7A). We
then performed a transient co-transfection experiment
with myogenin- and MyoD-expressing vectors, each with
the puromycin resistance-expressing vector, to select the
transfected cells, which were then analysed for p21WAF1
accumulation. Figure 7B shows that, despite the high
expression of ectopic proteins, no accumulation of
p21WAF1 was detected, suggesting that the increased level
of myogenic transcription factors alone does not induce
p21WAF1 expression. The failure of ectopic myogenin and
MyoD to increase p21WAF1 expression might be due to
inhibition of the myogenin and MyoD transactivating
function, or to an epigenetic modification of the p21WAF1
promoter, such as methylation, which frequently occurs
in tumor cells [35]. Luciferase assay from transiently co-
transfected cells with myogenin, MyoD or empty expres-
sion vectors with a p21WAF1 promoter-luciferase vector
(DM-Luc) showed an increased transactivating function
of both myogenin and MyoD when compared with the
empty vector (CMV) (Fig. 7C).
Taken together, these results suggest that, in RD cells,
enhanced myogenin or MyoD alone are able to at least
transactivate an ectopic p21WAF1 promoter, and that MEK/
ERK inhibition is required to relieve the inhibitory path-
way so as to fully restore the transactivating function of
endogenous myogenin and MyoD on the p21WAF1 pro-
moter.
p21WAF1 accumulation, though not myogenic 
differentiation, is a common feature of growth arrest in 
embryonal and alveolar rhabdomyosarcoma tumor-
derived cell lines
In order to verify whether the p21WAF1 expression and
growth arrest induced by the TPA and MEK inhibitor
U0126 are exclusive of the embryonal rhabdomyosar-
coma RD cell line, we also investigated the effects of both
these drugs on the alveolar rhabdomyosarcoma line
RH30. Figure 8 shows that after treating cells with TPA,
p21WAF1  expression was significantly induced from 6
hours up to 4 days, though to a lesser extent at 4 days
because there was a significant p21WAF1  increase in
untreated control cells. U0126 treatment also enhanced
p21WAF1 expression for the first 2 days, there being no
increased level of p21WAF1 thereafter (4 days) if compared
with the untreated control cells. Transient ERK pathway
activation by TPA and down-regulation by U0126 were
also detected. Similarly to RD cells, TPA and U0126 both
induced growth arrest of RH30 (Fig. 8B).
These data indicate that p21WAF1-enhanced expression is a
common feature of the growth inhibitory mechanism
induced by TPA and U0126 in the RH30 and RD cell lines.
Since both TPA and U0126 induce myogenic differentia-
tion markers in RD cells, we tested the expression of the
myosin heavy chain (MHC) in RH30 cells. As shown in
Figure 8C, unlike RD cells, neither TPA nor U0126
induced MHC expression. These preliminary data on
RH30 cells suggest that TPA and U0126 fail to induce the
myogenic program in spite of growth arrest.
Forced expression of p21WAF1 induces G1 arrest and 
reversion of anchorage-dependent growth of RD cells
The main role of p21WAF1 is to inhibit growth in normal
and transformed cells. In order to assess the effects on cell
growth of over-expression of p21WAF1 in the absence of
Effects of MEK/ERKs and p38 pathways on myogenic tran- scription factors and myosin expression Figure 6
Effects of MEK/ERKs and p38 pathways on myogenic 
transcription factors and myosin expression. RD cells 
were left untreated, treated with TPA, treated with SB 
203580 in the absence or in the presence of TPA and treated 
with U0126 in the absence or in the presence of TPA for the 
times indicated. Pre-treatment with SB 203580 or U0126 
was performed for 1 hour. Immunoblots of total lysates were 
performed using specific antibodies recognising myogenin, 
MyoD and sarcomeric myosin heavy chain (MHC). α-tubulin 
expression shows equal loading. The data shown are repre-
sentative of two independent experiments.
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p21WAF1 expression induced by U0126 is dependent on MyoD and/or myogenin Figure 7
p21WAF1 expression induced by U0126 is dependent on MyoD and/or myogenin. (A) Immunoblots of total lysates 
from RD cells transiently transfected with control-, MyoD- or myogenin-siRNA, or with a combination of MyoD- and myo-
genin-siRNA (MyoD+myogenin), and then left untreated (-) or treated with U0126 (+) for 2 days. (B) Immunoblots of total 
lysates from Puromycin-selected polyclonal population from RD cells transfected with the empty vector (CMV), MyoD- or 
myogenin-expressing vector. As a control, cells were left untransfected in the absence (C) or in the presence of TPA (TPA). 
Immunoblots were performed using specific antibodies capable of recognising MyoD, myogenin, p21WAF1 and α-tubulin. Densi-
tometric analysis of bands provided quantification of MyoD and myogenin levels expressed as a fold increase over the control 
value (CMV) arbitrarily set at 1. (C) Luciferase assay of lysates from RD cells co-transfected with the empty vector (CMV), 
myogenin- or MyoD-expressing vector and the plasmid carrying p21WAF1 promoter (DM-Luc). Data show mean values ± s.e.m. 
of triplicates of a representative experiment. Similar results were obtained in two experiments.
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other physiological disruptions, we transfected RD cells
either with vectors expressing p21WAF1 (CB6-p21) under
the control of the Zn+ inducible promoter [36] or with the
empty vector (CB6), subsequently selecting the trans-
fected cells with neomycin. p21WAF1  was strongly
expressed in a transiently transfected polyclonal popula-
tion and still over-expressed in a stably transfected poly-
clonal population of cells under ZnCl2 stimulation (Fig.
9A). p21WAF1 expression in stably transfected cells is com-
parable to that in untransfected TPA-treated cells, while
no p21WAF1 accumulation was observed in the empty vec-
tor. The growth potential of the p21WAF1-expressing cells
was assessed by culturing the two polyclonal populations
(CB6 and CB6/p21) for 3 days in the presence and in the
absence of 120µM ZnCl2, and comparing them with con-
trol, TPA- and U0126-treated untransfected cells. Figure
9B shows a representative experiment of growth analysis,
demonstrating 52% growth inhibition in p21WAF1-
expressing cells, if compared with the empty vector-
expressing cells, in the presence of ZnCl2. In addition,
Induction of p21WAF1 expression and growth arrest in RH30 cells treated with TPA and U0126 Figure 8
Induction of p21WAF1 expression and growth arrest in RH30 cells treated with TPA and U0126. (A) RH30 cells 
treated with 10 -7 M TPA (T) or 10 µM U0126 (U) for the times indicated. Whole cell lysates were analysed by immunoblotting 
with a specific antibody for p21WAF1, phosphorylated ERK1/2 and α-tubulin expression. (B) Growth graph of RH30 and RD 
cells after 4 days of TPA (T) or U0126 (U) treatments. (C) Immunoblot of total lysates using specific antibody capable of recog-
nising the sarcomeric myosin heavy chain (MHC). Similar results were obtained in two experiments.
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Enforced p21WAF1 expression induces growth arrest in RD cells Figure 9
Enforced p21WAF1 expression induces growth arrest in RD cells. (A) Immunoblotting using specific antibody capable of 
recognising the p21WAF1 of total lysates from RD cells transfected with CB6/p21 or the empty vector (CB6), cultured without 
(-) or with 120 µM ZnCl2 (+) for 3 days before (Transient transfection) and after (Stable transfection) neomycin-selection. (B) 
Growth graph of same neomycin-selected RD cells cultured as in A. As a control, untransfected RD cells were left untreated 
(C) or treated with TPA or U0126. (C) Cell cycle distribution of RD cells transfected with empty vector PEGFP (left) or with 
PEGFP/p21 (right). Cell cycle distribution of GFP-expressing cells was evaluated by flow cytometry. The data shown in the 
insert tables are the mean ± s.e.m. of triplicates of a representative experiment. Similar results were obtained in two experi-
ments.
CB6
CB6/P21
CB6
CB6/P21 
Transient 
transfection
Stable 
transfection
p21
A
B
C
PEGFP PEGFP-p21
C
TPA
U0126
α α α α-tubulin
MHC
19.4+ 0.7 S
10.6+ 0.2 G2/M
69.9+ 0.9 G1
4.2+ 0.4 S
8+ 0.3 G2/M
87.7+ 0.1 G1
CB6
CB6/P21
CB6
CB6/P21 
0
2
4
6
8
10
12
14
16
C
T
P
A
C
B
6
U
0
1
2
6
C
B
6
 
+
 
Z
n
C
B
6
/
p
2
1
C
B
6
/
p
2
1
 
+
 
Z
n
N
°
 
c
e
l
l
s
/
p
l
a
t
e
 
x
1
0
-
5
ZnCl2 --++ --++Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
Page 13 of 18
(page number not for citation purposes)
53% and 80% inhibition was observed respectively in
TPA- and U0126-treated cells (Fig. 9B). We also per-
formed a FACS analysis using RD cells transfected with a
vector expressing p21WAF1-GFP fusion protein (PEGFP-
p21WAF1) and with a vector devoid of p21WAF1 (PEGFP).
The use of GFP-p21WAF1 transfected cells permits cell cycle
analysis in GFP-fluorescent transfected cells alone. The
results of the FACS analysis demonstrate that after 48
hours of p21WAF1 over-expression, DNA replication had
ceased (4.6 fold reduction in cells in S-phase) and cells
were arrested primarily in G1 (87.7% in G0/G1, Fig. 9C).
We then investigated whether the reduced growth poten-
tial of p21WAF1-expressing RD cells is accompanied by
reduced anchorage-independent growth, as has been
demonstrated in the astrocytoma cell line [37]. We per-
formed a soft agar clonogenic assay using stably CB6- and
CB6-p21-transfected RD cells in the presence and absence
of 120µM ZnCl2. The results, shown in Figure 10, demon-
strate that RD cells expressing the empty vector (CB6)
grew in the agar, forming several colonies not affected by
ZnCl2 treatment. ZnCl2-mediated p21WAF1 expression dra-
matically reduced colony formation (CB6/p21 Zn2+),
whereas the absence of ZnCl2 stimulation did not (CB6/
p21) (Fig. 10).
Discussion
ERK pathway activation or inhibition induce p21WAF1 
expression post-transcriptionally or transcriptionally
During the myogenic process of cultured cell lines,
p21WAF1 expression is controlled by myogenic transcrip-
tion factors such as MyoD [10,11]. In ERMS-derived RD
cells with transcriptional inactive mutated p53, the myo-
genic transcription factors, MyoD and myogenin, are,
despite being expressed, inactive [23,27]. Inactivation of
p53 and myogenic transcription factors might explain the
low level of p21WAF1 expression. In this paper, we have
addressed the issue of how ERK pathway activation or
inhibition induce growth arrest and expression of myo-
genic-specific genes. We show that p21WAF1 accumulation
is a convergence point of growth arrest signals induced by
the activation or inhibition of ERKs. Nevertheless,
p21WAF1 accumulation varies in its extent and length of
expression, it being strong and sustained after ERK activa-
tion (TPA) but transient after MEK/ERK inhibition
(U0126). It is noteworthy that in U0126-treated cells, CKI
inhibitor p27 expression increases concomitantly with
p21WAF1 and is sustained during treatment. Interestingly,
when p21WAF1 expression drops, p27 peaks and cyclin D1
drops as well. As a result of p21WAF1-mediated inhibition
of the growth pathway, the hypo-phosphorylated/active
form of pRb is expressed early (12 hrs) and predomi-
nantly in U0126-treated cells, and later (2 days) in TPA-
treated cells.
The concomitant increase in cyclin D1 in TPA-treated cells
and its decrease in U0126-treated cells may explain the
stronger growth arrest response after U0126 treatment.
Nevertheless, TPA-mediated withdrawal from the cell
cycle may be supported by decreased cyclin A and B
expression. This cell cycle expression pattern fails in
untreated control cells, though the level of p21WAF1 may
increase as a result of culture conditions, i.e. cell conflu-
ence. Lastly, since p27 and p21WAF1 may act as assembly
factors [4], it is possible that the early exit from the cell
cycle in U0126-treated cells is due to a combined action
of p21WAF1 and p27, the sustained G1 arrest then being
ensured by p27 expression and by cyclin D1 loss. Regula-
tion of p27 expression is reported to be dependent on
transcriptional, post-transcriptional or protein stability
mechanisms [38,39]. Nevertheless, although unable to
discuss the precise mechanism of p27 increased expres-
sion by MEK inhibitor, on the basis of the above discussed
results we hypothesize an involvement of p27 in growth
arrest of RD cells, as it has recently been demonstrated in
pancreatic cancer cells treated with MEK inhibitor U0126
[40].
As reported in the literature, p21WAF1 expression is mainly
a result of ERK activation in a number of cell types [8,9],
though it may also be due to ERK inhibition, as occurs in
Enforced p21WAF1 expression induces reversion of anchorage  independent growth Figure 10
Enforced p21WAF1 expression induces reversion of 
anchorage independent growth. Neomycin-selected RD 
cells transfected with CB6/p21 or the empty vector (CB6) 
were suspended in 0.33% Difco agar in the absence (CB6, 
CB6/p21) or presence (CB6 Zn2+, CB6/p21 Zn2+) of 120 µM 
ZnCl2 and overlaid on an 0.5% agar layer. Colonies were 
photographed after 14 days. Similar results were obtained in 
two experiments.Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
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MCF7 cells [41]. We hypothesise that prolonged ERK acti-
vation plays an important role in supporting long-lasting
p21WAF1 expression in RD cells on the basis of the follow-
ing results: i) U0126 prolonged treatment reduces TPA-
mediated p21WAF1 expression; ii) enforced expression of
constitutively active MEK1 or MEK2 induces both
increased p21WAF1 expression and ERK pathway activa-
tion; iii) the depletion of ERK1 and ERK2 by siRNA,
besides abrogating ERK1/2 expression, prevents TPA-
mediated p21WAF1 expression. Overall, these data prove
that activation of ERKs mediates sustained p21WAF1
expression. Nevertheless, while investigating the mecha-
nisms controlling p21WAF1 expression, we found that TPA
induces p21WAF1  mRNA stabilization, which is fully
responsible for p21WAF1 accumulation, whereas U0126
induces p21WAF1 -increased expression solely through a
transcriptional mechanism. The post-transcriptional
mechanism of p21WAF1 induction after TPA treatment is in
keeping with previous studies in the literature reporting
PKC-mediated p21WAF1 mRNA stabilization [7].
Notably, both TPA and U0126 induce p21WAF1 expression
in the RH30 alveolar rhabdomyosarcoma cell line, with
concomitant growth arrest. Although further investigation
of the molecular mechanisms in the alveolar cell line is
required, our findings suggest that p21WAF1 is involved in
the early growth arrest. Indeed, ERK inhibition by U0126
or activation by TPA occur in the early stages of treat-
ments, not in the later stages. We may hypothesize that in
U0126-treated RH30 cells the active ERK pathway can be
restored without altering cell responsiveness to the
growth-arresting signal. We are currently investigating
whether these transient effects on the ERK pathway imply
the involvement of other kinase pathways.
Growth arrest of RD cells has previously been studied by
one group that reported an increase in the expression of
p27 and p21WAF1 without induction of growth arrest due
to high levels of cyclins, CDKs and phospho-Rb, and by
another group that reported a role of butyrate-induced
p21WAF1 and p27 in RD and RH30 cell line growth arrest
[26,42]. Under our conditions, TPA and the MEK inhibi-
tor disrupt a growth-signalling pathway, by affecting the
MAPK cascade, and drive the cells to growth arrest and, in
RD cells, myogenic differentiation (see below). This is of
particular interest in light of the possibility of reversing
the transformed phenotype through mechanisms, which
modulate the MEK/ERK pathway.
p38 and the ERK pathways do not cooperate in growth 
arrest
The apparently contrasting result regarding the activation
or inhibition of the MEK/ERK pathway, both as a cause of
growth arrest and myogenic differentiation, might reflect
the involvement of other MAPK pathways, MAPK-p38
being the most likely candidate. Indeed, cooperation
between ERK and p38 pathways in p21WAF1-dependent
G1 cell cycle arrest has recently been reported [20]. On the
other hand, the effects of ERK and p38 are reported to be
dependent, respectively, on the high ERK/p38 ratio in
tumor growth and on the high p38/ERK ratio in tumor
arrest [18].
For these reasons, we investigated the role of the p38 path-
way in p21WAF1 accumulation, using the SB203580 p38
inhibitor during treatment by TPA and U0126, both pre-
viously shown by us to induce phospho/active p38 [30].
We found that the transcriptional, but not post-transcrip-
tional mechanism of p21WAF1 expression is regulated by
the p38 pathway. A significant role of p38 both in growth
arrest and in myogenic differentiation has recently been
reported [43,44] in normal and pathological myogenic
lines expressing the ectopic upstream kinase of p38. How-
ever, our results are in agreement with these data, p38
inhibition being inhibitory on U0126-mediated tran-
scriptional mechanism of p21WAF1 and myogenic tran-
scription factors expression induced by both TPA and
U0126, but is not effective on p21WAF1 expression induced
by TPA. As a consequence of p38 inhibition, the levels of
the hypo-phosphorylated/active form of pRb in
SB203580-treated cells are affected only after prolonged
treatments with U0126. Conversely, neither the pRb
phosphorylation status nor p21WAF1 accumulation by TPA
are impaired by the p38 inhibitor. It is noteworthy that
the ERK/p38 ratio is predictive of growth status in a
number of tumor cells [18], which suggests that, on the
basis of our previous investigation [30], U0126-mediated
ERK down-regulation and the sustained increase in phos-
pho-active p38 favours persistent growth suppression.
Myogenic transcription factors and muscle specific genes 
in embryonal and alveolar rhabdomyosarcoma
Both the MEK-ERK inhibitor and TPA induce myogenic-
specific gene expression, with MHC accumulation in
U0126-treated cells occurring earlier than in TPA-treated
cells. Early myogenin accumulation followed by MyoD
shows that the myogenic program is rapidly rescued in
ERK-depleted cells.
Cyclin D1 might also be responsible for the delay in the
activation of myogenic transcription factors [45] in TPA-
treated cells; by contrast, cyclin D1 is down-regulated by
U0126 alone or together with TPA, leading to a rapid start
of the myogenic program. Remarkably, myogenin and
MyoD expression, strongly induced by U0126 in both the
presence and absence of TPA, are down-regulated by the
p38 inhibitor, thereby paralleling the pattern observed in
p21WAF1 expression. In view of these results, we hypothe-
size that MyoD, as previously shown in normal myogene-
sis [10,11], and even myogenin might transactivateMolecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
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p21WAF1 expression in MEK inhibitor-treated cells. Indeed,
U0126-mediated p21WAF1 expression requires myogenin
and MyoD, as demonstrated by its drastic inhibition in
myogenin and MyoD siRNA experiments. However,
MyoD- or myogenin-forced expression in RD cells, while
inducing an ectopic p21WAF1 promoter, does not induce
an increase in the p21WAF1 level. The discrepancy between
the inability of forced myogenin and MyoD expression to
induce p21WAF1 and the ability of these two transcription
factors to transactivate an ectopic promoter, in transfected
RD cells, suggests that inhibitory pathways responsible for
p21WAF1 repression operate at the level of the p21WAF1
endogenous promoter. It is noteworthy that the authors
of another study [43] did not detect p21WAF1 promoter
transactivation by ectopic MyoD in RD cells. However,
this discrepancy may depend on differences in the experi-
mental approach used as the authors of that study
addressed the issue of whether the upstream p38 kinase,
namely MKK6E, synergistically affects MyoD transactivat-
ing function. We are mainly interested in clarifying
whether the rescue of myogenic transcription factors
expression and functions might be responsible for the
restored p21WAF1  transcription. Our results specifically
concerning the positive role of the p38 pathway in
p21WAF1 transcription are, however, in agreement with
those reported in the aforementioned study. Indeed, p38
inhibitor was found to drastically inhibit the myogenic
transcription factor as well as p21WAF1 and sarcomeric
myosin expression. Thus, it is possible that MEK/ERK
inhibition, following U0126 treatment, leads to p21WAF1
transcription by unmasking of the transcriptional site tar-
gets of MyoD and myogenin, on the one hand, and directs
RD cells towards growth arrest and the differentiation pro-
gram by enhancing myogenic transcription factors levels,
on the other. Unlike RD cells, RH30 cells do not undergo
myogenic differentiation despite being induced to growth
arrest.
Ectopic p21WAF1 induces growth arrest and reversal of the 
onco-phenotype independently of the ERK pathway
The role of p21WAF1 in RD cell growth arrest is demon-
strated here by the growth inhibition (53%) induced by
forced expression of the p21WAF1 inducible vector and by
the FACS analysis of RD cells transfected with p21WAF1-
GFP.
These results, together with our previous data on early G1
arrest in ERK pathway-depleted cells [30], suggest that
p21WAF1 and the rescue of myogenic transcription factor
functions play a role in dismantling the proliferative
incentive, thereby rapidly driving the cells to G1 arrest.
In view of these results, combined with the body of evi-
dence showing that p21WAF1 functions as a tumor suppres-
sor, we tested focus formation in soft agar of p21WAF1
stably transfected RD cells, revealing a dramatic loss of
anchorage independent growth. This result demonstrates
that p21WAF1 is, by itself, able to override the transforming
potential of RD cells. These data, though promising with
regard to the role of p21WAF1 alone in reverting malignant
growth, warrant further research on the anchorage inde-
pendent growth pathways that may be affected by high
p21WAF1 levels.
Conclusion
In this study we highlight the importance of targeting the
MEK/ERK pathway as a means of restoring the expression
of the tumor suppressor p21WAF1 as well as the growth
arrest mechanism. The results of this study suggest that the
targeting of ERKs to rescue p21WAF1 expression and myo-
genic transcription factor functions leads to the reversal of
the Rhabdomyosarcoma phenotype. The inhibition of the
MEK/ERK pathway might, therefore, prove to be a novel
therapeutic approach for the reversal of the Rhabdomy-
osarcoma phenotype.
Methods
Cell cultures and treatments
The human embryonal RD (ATCC, Rockville MD) and
alveolar RH30 (DSMZ, Braunschweig, Germany) rhab-
domyosarcoma cells were cultured respectively in Dul-
becco's modified Eagle's and RPMI medium containing
10% fetal calf serum (Hyclone, Logan UT) supplemented
with glutamine and gentamycin (GIBCO-BRL Gaithers-
burg, MD). One day after plating, cells were treated with
10-7 M TPA (Sigma, St. Louis, MO) or with 10 µM kinase
inhibitors U0126 (Promega, Madison, WI) and/or 5 µM
SB203580, or SB202474 as a negative control (Calbio-
chem, La Jolla CA), for the times shown in the figures.
Actinomycin D (0.05 µg/ml) was incubated for 1 hr
before stimulation with TPA or U0126, in complete
medium; cycloheximide (10µM) (Sigma, St. Louis, MO)
was incubated after 1 hr of TPA treatment in complete
medium.
Immunoblot analysis
Cells were lysed in 2% SDS containing 2 mM phenyl-
methyl sulphonyl fluoride (PMSF) (Sigma), 10 µg/ml
antipain, leupeptin and trypsin inhibitor, 10 mM sodium
fluoride and 1 mM sodium orthovanadate (all from
Sigma) and sonicated for 30 sec. Proteins of whole cell
lysates were assessed using the Lowry method [46], and
equal amounts were separated on SDS-PAGE. The pro-
teins were transferred to a nitrocellulose membrane (Sch-
leicher & Schuell, BioScience GmbH, Germany) by
electroblotting. The balance of total protein levels was
confirmed by staining the membranes with Ponceau S
(Sigma). Immunoblottings were performed with the fol-
lowing antibodies: anti-p21 (C-19), anti-cyclin D1 (M-
20) and D3 (C-16), E (HE12), A (H-432) and B (H-20)Molecular Cancer 2005, 4:41 http://www.molecular-cancer.com/content/4/1/41
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cyclins, CDK2 (M2) and 4 (H-22), -pRb (C-15), anti-myo-
genin (F-D5), anti-ERK2 (C-14, positive also for ERK1)
anti-phospho-ERKs (E-4) and α-tubulin (B-7) (all from
Santa Cruz Biotechnology, Santa Cruz CA), MyoD (clone
5.8A, Novocastra Newcastle, UK, or C-20 from Santa Cruz
Biotechnology) and anti-MHC (MF20, gift from Fichman
D). Peroxidase-conjugate anti-mouse or anti-rabbit IgG
(Amersham-Pharmacia Biotech, UK or Santa Cruz) were
used for enhanced chemiluminescence (ECL) detection.
Northern blot analysis
Cells were collected and lysed in Trizol reagent (GIBCO-
BRL). Total RNA was isolated according to the manufac-
turer's instructions. 10 µg of total RNA was resolved on a
formaldehyde/agarose gel, and transferred to GeneScreen
Plus (DuPont, Bad Homburg, Germany) membranes. Fil-
ters were cross-linked by baking at 80°C for 2 hrs, then
hybridised overnight with 1 × 106 to 2 × 106 cpm of 32P
labelled DNA probes per ml. DNA probes were labelled
by random priming to a specific activity of approximately
0.5 × 109 cpm/µg. The membranes were washed at a final
stringency of 0.1 × SSC, 0.5% SDS at 60°C. The p21WAF1,
MyoD and myogenin probes was obtained from the plas-
mid described below, while cyclin D1 probe was kindly
provided by Dr. A. Arnold [47] and GAPDH vector was
provided by ATCC.
Plasmids and transfections
One day after plating, RD cells were transfected with all
the plasmids using Lipofectamine Plus reagent (Invitro-
gen, Italy) according to the manufacturer's instructions
(GIBCO-BRL, Gaithersburg, MD). RNA interference
experiments were performed with siRNA for ERK1 and
ERK2, myogenin and/or MyoD (Sancta Cruz Biotechnol-
ogy) using Lipofectamine 2000 reagent (Invitrogen, Italy),
according to the manufacturer's instructions. Briefly, cells
were plated at 40–50% confluence and transfected after
24 hr with 100 nM siRNA, which we ascertained was suf-
ficient to detect maximum fluorescence using fluorescein-
conjugated control siRNA. For the luciferase assay, the
human p21WAF1 promoter construct DM-Luc (gift from
Dr. P. Dotto) was co-tranfected into RD cells together with
CMV  β-Galactosidase expressing vector as the internal
standard to control for transfection efficiency. One day
after transfection, cells were treated with TPA or left
untreated for 24 hrs. Total lysates were processed for luci-
ferase activity according to the manufacturer's instructions
(Promega Italia). Luciferase activity was normalized for
the expression level of transfected β-Galactosidase protein
[48]. Alternatively, DM-Luc was co-transfected with plas-
mid expressing MyoD [49] or myogenin [50]; after 48 hrs,
cells were harvested, lysed and processed for luciferase
activity as described above. For p21WAF1 expression analy-
sis, RD cells were also transiently transfected with: MyoD
or myogenin together with puromycin resistance-express-
ing vectors (pPur, Clontech laboratories Gmbh, Heidel-
berg, Germany) to select transfected cells with puromycin
(4µg/ml); with constitutively active MEK1 or MEK2
kindly provided by N. Ahn [51]. After 48 hours, cells were
harvested, lysed and processed for immunoblotting. RD
cells stably expressing p21WAF1 or the empty vector were
prepared by transfecting cells with a plasmid encoding full
length human p21WAF1, aa 1–164 (Zinc-inducible vector
pMT-CB6/p21) and the empty vector (Zinc-inducible
pMT-CB6) carrying neomycin resistance, donated by
Asada M [36], followed by selection in G418 (0.5 mg/ml)
for 3 weeks. G418-resistant clones were pooled for a rep-
resentative stock of stably transfected cells and re-plated
for stimulation with 120 µM ZnCl2 for 3 days. Cells were
processed both for p21WAF1 expression analysis and for the
number of cells counted in the hemocytometer chamber.
For transient expression of both pEGFP-p21WAF1  full
length and pEGFP (gift from Asada M.), RD cells were
transfected and collected for FACS analysis 24 hrs later.
FACS analysis
Cells were harvested by trypsin-EDTA and washed; pellets
were then resuspended in PBS additioned with 1% para-
formaldehyde (final concentration of 0.5%) left at 4°C
for 1 hr. The fixed cells were then washed with PBS twice,
resuspended in 0.3 ml of 50% FCS in PBS, additioned
with 0.9 ml of 70% ethanol and left at 4°C in the dark for
no longer than 2 days before FACS analysis (Coulter Epics
XL Flow Cytometer, Beckman Coulter Ca, USA).
Colony-forming assays in semisolid agar
Colony-forming assays were based on standard methods.
Briefly, 2 × 104  cells were resuspended in 4 ml of 0.33%
special Noble agar (Difco, Detroit, MI) and plated (6 cm
plate) in growth medium containing 0.5% soft agar. Col-
onies were photographed 14 days after plating.
List of abbreviations
RD, rhabdomyosarcoma cell line; MEK, Mitogen-acti-
vated protein Extracellular Kinase; ERK, Extracellular sig-
nal-Regulated protein Kinase.
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